In the past week, ADMA stock has gone down by -16.07%, with a monthly decline of -3.51% and a quarterly surge of 27.18%. The volatility ratio for the week is 8.68%, and the volatility levels for the last 30 days are 5.20% for Adma Biologics Inc The simple moving average for the past 20 days is -12.21% for ADMA’s stock, with a 66.55% simple moving average for the past 200 days.
Is It Worth Investing in Adma Biologics Inc (NASDAQ: ADMA) Right Now?
Adma Biologics Inc (NASDAQ: ADMA) has a higher price-to-earnings ratio of 121.12x compared to its average ratio. ADMA has 36-month beta value of 0.63. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADMA is 225.20M, and currently, short sellers hold a 7.58% ratio of that float. The average trading volume of ADMA on October 11, 2024 was 5.11M shares.
ADMA) stock’s latest price update
Adma Biologics Inc (NASDAQ: ADMA)’s stock price has increased by 0.12 compared to its previous closing price of 17.01. However, the company has seen a -16.07% decrease in its stock price over the last five trading sessions. accesswire.com reported 2024-10-11 that NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. (“ADMA Biologics, Inc.”) (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at -3.25% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.40% of loss for the given period.
Volatility was left at 5.20%, however, over the last 30 days, the volatility rate increased by 8.68%, as shares sank -6.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.82% upper at present.
During the last 5 trading sessions, ADMA fell by -16.76%, which changed the moving average for the period of 200-days by +287.39% in comparison to the 20-day moving average, which settled at $19.39. In addition, Adma Biologics Inc saw 276.77% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Guiheen Lawrence P., who sale 9,000 shares at the price of $18.47 back on Sep 09 ’24. After this action, Guiheen Lawrence P. now owns 153,941 shares of Adma Biologics Inc, valued at $166,189 using the latest closing price.
Guiheen Lawrence P., the Director of Adma Biologics Inc, proposed sale 9,000 shares at $16.26 during a trade that took place back on Sep 09 ’24, which means that Guiheen Lawrence P. is holding shares at $146,340 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.46 for the gross margin
The net margin for Adma Biologics Inc stands at 0.11. The total capital return value is set at 0.25. Equity return is now at value 20.77, with 9.67 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.55. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is 4.16.
Currently, EBITDA for the company is 29.96 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 12.23. The receivables turnover for the company is 10.97for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.87.
Conclusion
To put it simply, Adma Biologics Inc (ADMA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
